Press release
Chronic Kidney Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata The
DelveInsight's, "Crohn's disease - Pipeline Insight, 2025" report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in Crohn's disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.Chronic Kidney Disease Pipeline constitutes 80+ key companies continuously working towards developing 85+ Chronic Kidney Disease treatment therapies, analyzes DelveInsight.
Chronic Kidney Disease Overview:
Chronic Kidney Disease (CKD) is a long-term condition characterized by the gradual loss of kidney function over time. The kidneys are essential for filtering waste, excess fluids, and electrolytes from the bloodstream, which are excreted in urine. As CKD worsens, it can lead to kidney failure, requiring dialysis or a kidney transplant to sustain life. The condition is categorized into five stages, with Stage 1 being mild and Stage 5 indicating end-stage renal disease (ESRD).
CKD often develops silently, with few or no symptoms in the early stages. As it progresses, individuals may experience fatigue, swelling in the legs and ankles, appetite loss, nausea, vomiting, shortness of breath, itching, and changes in urination. In advanced stages, complications such as high blood pressure, anemia, bone weakness, and nerve damage may occur. Severe cases can lead to uremia, a dangerous buildup of toxins in the blood, which may cause confusion, difficulty concentrating, or seizures.
The most common causes of CKD are diabetes and high blood pressure. Other contributing factors include glomerulonephritis, polycystic kidney disease, chronic urinary tract obstructions, repeated kidney infections, and autoimmune disorders like lupus. The disease progresses due to a combination of factors such as increased pressure in the kidney's filtering units (glomerular hyperfiltration), ongoing inflammation, tissue scarring (fibrosis), and cell damage, all of which contribute to declining kidney function over time.
Request for a detailed insights report on Chronic Kidney Disease pipeline insights [https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Chronic Kidney Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Chronic Kidney Disease Therapeutics Market.
Key Takeaways from the Chronic Kidney Disease Pipeline Report
*
DelveInsight's Chronic Kidney Disease pipeline report depicts a robust space with 80+ active players working to develop 85+ pipeline therapies for Chronic Kidney Disease treatment.
*
In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. FDA had accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC). The FDA has set a target action date of June 28, 2025, under the Prescription Drug User Fee Act (PDUFA). If approved, OLC could represent a significant breakthrough in treating hyperphosphatemia in chronic kidney disease (CKD) patients undergoing dialysis.
*
In March 2023, Boehringer Ingelheim shared promising Phase II results for BI-690517, a novel selective aldosterone synthase inhibitor (ASI). The 14-week study showed a substantial reduction in albuminuria, a key indicator of kidney damage, by up to 39.5% when BI-690517 was combined with empagliflozin, an SGLT2 inhibitor, compared to a placebo. This was the first clinical trial to evaluate this new treatment class alongside standard care in CKD patients, with the results presented at the American Society of Nephrology's Kidney Week 2023.
*
Key Chronic Kidney Disease companies such as Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata Therapeutics, Unicycive Therapeutics, Novo Nordisk, Bayer, AstraZeneca, Roche, MC2 Therapeutics, Allena Pharmaceuticals, Boehringer Ingelheim, SCOHIA PHARMA, Regeneron Pharmaceuticals, UnicoCell Biomed, OccuRx, Disc Medicine, Shandong Suncadia Medicine, Sarfez Pharmaceuticals, Rege Nephro, Orgenesis, Healx, Benevolent, and others are evaluating new drugs for Chronic Kidney Disease to improve the treatment landscape.
*
Promising Chronic Kidney Disease pipeline therapies in various stages of development include Ziltivekimab, Rilparencel, US-APR2020, XRx-008, CLBS201, UNI-494, and others.
Chronic Kidney Disease Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Chronic Kidney Disease Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Chronic Kidney Disease treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Chronic Kidney Disease market.
Download our free sample page report on Chronic Kidney Disease pipeline insights [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Chronic Kidney Disease Emerging Drugs
*
Ziltivekimab: Novo Nordisk
*
Rilparencel: Prokidney
*
US-APR2020: Kibow Pharma
*
XRx-008: XORTX Therapeutics
*
CLBS201: Lisata Therapeutics
*
UNI-494: Unicycive Therapeutics
Chronic Kidney Disease Companies
More than 80 major companies are actively developing treatments for Chronic Kidney Disease (CKD). Among these, Novo Nordisk has advanced its drug candidates to the furthest stage of development-Phase III clinical trials.
DelveInsight's report covers around 85+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Chronic Kidney Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Chronic Kidney Disease Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Chronic Kidney Disease Therapies and Key Companies: Chronic Kidney Disease Clinical Trials and advancements [https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Chronic Kidney Disease Pipeline Therapeutic Assessment
- Chronic Kidney Disease Assessment by Product Type
- Chronic Kidney Disease By Stage
- Chronic Kidney Disease Assessment by Route of Administration
- Chronic Kidney Disease Assessment by Molecule Type
Download Chronic Kidney Disease Sample report to know in detail about the Chronic Kidney Disease treatment market @ Chronic Kidney Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Chronic Kidney Disease Current Treatment Patterns
4. Chronic Kidney Disease - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Chronic Kidney Disease Late-Stage Products (Phase-III)
7. Chronic Kidney Disease Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Chronic Kidney Disease Discontinued Products
13. Chronic Kidney Disease Product Profiles
14. Chronic Kidney Disease Key Companies
15. Chronic Kidney Disease Key Products
16. Dormant and Discontinued Products
17. Chronic Kidney Disease Unmet Needs
18. Chronic Kidney Disease Future Perspectives
19. Chronic Kidney Disease Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Chronic Kidney DiseaseO Pipeline Reports Offerings [https://www.delveinsight.com/report-store/chronic-kidney-disease-ckd-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-kidney-disease-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-novo-nordisk-prokidney-kibow-pharma-xortx-therapeutics-lisata-the]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Chronic Kidney Disease Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Novo Nordisk, Prokidney, Kibow Pharma, XORTX Therapeutics, Lisata The here
News-ID: 4096622 • Views: …
More Releases from ABNewswire

Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…

Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…

Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…

HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Kidney
Surging Chronic Kidney Cases Propel Growth In The Artificial Kidney Market: Tran …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Artificial Kidney Industry Market Size Be by 2025?
The market size for artificial kidneys has experienced swift expansion in the latest years. The market is predicted to escalate from $10.22 billion in 2024 to $11.43 billion in 2025, with a compound annual growth rate (CAGR) of…
Chronic Kidney Diseases Fueling Kidney Stone Retrieval Device Growth Driving Mar …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Kidney Stone Retrieval Devices Market Size By 2025?
In recent times, the market size for kidney stone retrieval devices has seen consistent growth. The market, which is projected to increase from $2.84 billion in 2024 to $2.96 billion in 2025, forecasts a compound annual growth…
Wearable Artificial Kidney Market Development Trajectory through 2031 Dutch Kidn …
"[New York, December 2024] The Wearable Artificial Kidney represents a groundbreaking innovation in nephrology that combines advanced biomedical engineering with portable technology. Designed to continuously filter waste from the blood, this device caters primarily to patients with chronic kidney disease. As renal health issues become more prevalent globally, the relevance of the Wearable Artificial Kidney lies in its potential to enhance patient quality of life, providing a more convenient and…
Kidney Dialysis Market Share Kidney Dialysis Market
According to Ameco Research 'Kidney Dialysis Market report, the analysts took this into account when estimating the Kidney Dialysis Market size and CAGR for the respective industry. The report's author has thoroughly examined the market and concluded that the Kidney Dialysis Market 's growth will level off in the coming years. In addition to that, the prominent qualitative information added in the report includes Kidney Dialysis Market trends, segmentation, key…
Kidney Health Journey: Polycystic Kidney Disease Drug Pipeline Landscape (2023-2 …
Market Outlook:
The Polycystic Kidney Disease (PKD) drug pipeline landscape is poised for noteworthy advancements, offering a positive outlook for those navigating the complex journey of kidney health. As PKD poses a significant global health burden, the market outlook reflects a pressing need for innovative pharmaceutical interventions to address the challenges associated with this genetic disorder. With ongoing research and development efforts, the PKD drug pipeline is positioned to bring…
Kidney Balloon Market Growth Drives By Rising Prevalence of Kidney Stone and Oth …
Demand Analysis of Kidney Balloon Market Overview:
Kidney Balloon Market is predicted to grow at a moderate CAGR of 5.2% during the forecast period covering 2022 to 2029. Kidney Balloon Market share is estimated to reach a value of nearly US$ 2.50 Billion by 2029.
The "Kidney Balloon Market" think about 2022, the industry landscape is secured from driving factors to upstream markets and the by and large state of the market.…